MedTrace Logo

Topical Imiquimod in Conjunction With Nd:YAG Laser for Tattoo Removal

NCT00638651 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2018-03-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy of tattoo removal using topical imiquimod, 5% cream in conjunction with the 1064nm Nd:YAG laser. This procedure for tattoo removal will be compared to a laser removal alone.

Conditions

  • Healthy

Interventions

DEVICE

1064 nm Nd:YAG laser

The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy

DRUG

Imiquimod, 5% cream

2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month

Sponsors & Collaborators

  • University of Miami

    lead OTHER

  • Graceway Pharmaceuticals, LLC

    collaborator INDUSTRY

Principal Investigators

  • Keyvan Nouri, MD · University of Miami

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2014-08-31
Completion
2014-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00638651 on ClinicalTrials.gov